(ARWR) Arrowhead Pharmaceuticals - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US04280A1007
Stock: RNAi, Hepatic, Metabolic, Cardiovascular, Rare
Total Rating 59
Risk 33
Buy Signal -0.90
| Risk 5d forecast | |
|---|---|
| Volatility | 67.3% |
| Relative Tail Risk | -9.15% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.00 |
| Alpha | 214.25 |
| Character TTM | |
|---|---|
| Beta | 2.102 |
| Beta Downside | 2.493 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.86% |
| CAGR/Max DD | 0.42 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: ARWR Arrowhead Pharmaceuticals February 25, 2026
Arrowhead Pharmaceuticals (NASDAQ: ARWR) focuses on RNA-interference (RNAi) therapeutics targeting genes that drive hard-to-treat metabolic and cardiovascular diseases. Its lead pipeline features Plozasiran (apoC-III) and Zodasiran (ANGPTL3), both in Phase 3 trials, alongside a suite of early-stage RNAi candidates (ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE, ARO-ALK7, ARO-RAGE, ARO-MAPT, ARO-C3, ARO-CFB) in Phase 1/2a studies. The company leverages collaborations with GSK, Takeda, Amgen and Sarepta to expand development and commercialization capabilities.
As of the latest Q4 2025 filing, Arrowhead reported $210 million of cash and marketable securities, giving it roughly an 18-month runway at current burn rates. In July 2025, the Plozasiran Phase 3 trial achieved its primary endpoint, showing a 45 % reduction in triglycerides versus placebo, while the Zodasiran trial is on track for readout in early 2026. The RNAi sector is experiencing strong tailwinds, with analysts projecting a 13 % CAGR through 2030 driven by growing FDA approvals and expanding payer acceptance for gene-silencing therapies.
For a deeper dive into ARWR’s valuation metrics, you might explore ValueRay’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 202.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 76.46 > 1.0 |
| NWC/Revenue: 75.80% < 20% (prev 1828 %; Δ -1752 % < -1%) |
| CFO/TA 0.21 > 3% & CFO 339.3m > Net Income 202.3m |
| Net Debt (111.1m) to EBITDA (370.2m): 0.30 < 3 |
| Current Ratio: 3.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (140.7m) vs 12m ago 12.70% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 83.35% > 50% (prev 2.57%; Δ 80.77% > 0%) |
| Interest Coverage Ratio: 3.83 > 6 (EBITDA TTM 370.2m / Interest Expense TTM 90.2m) |
Altman Z'' 0.31
| A: 0.52 (Total Current Assets 1.17b - Total Current Liabilities 347.4m) / Total Assets 1.60b |
| B: -1.00 (Retained Earnings -1.60b / Total Assets 1.60b) |
| C: 0.26 (EBIT TTM 345.1m / Avg Total Assets 1.31b) |
| D: -1.53 (Book Value of Equity -1.59b / Total Liabilities 1.04b) |
| Altman-Z'' Score: 0.31 = B |
Beneish M 1.00
| DSRI: 2.09 (Receivables 218.9m/2.50m, Revenue 1.09b/26.1m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.44 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 41.82 (Revenue 1.09b / 26.1m) |
| TATA: -0.09 (NI 202.3m - CFO 339.3m) / TA 1.60b) |
| Beneish M-Score: 26.72 (Cap -4..+1) = D |
What is the price of ARWR shares?
As of March 07, 2026, the stock is trading at USD 59.82 with a total of 2,764,978 shares traded.
Over the past week, the price has changed by -5.45%, over one month by -7.28%, over three months by -12.80% and over the past year by +238.54%.
Over the past week, the price has changed by -5.45%, over one month by -7.28%, over three months by -12.80% and over the past year by +238.54%.
Is ARWR a buy, sell or hold?
Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy ARWR.
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARWR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.4 | 36% |
| Analysts Target Price | 81.4 | 36% |
ARWR Fundamental Data Overview March 05, 2026
P/E Trailing = 40.0625
P/E Forward = 111.1111
P/S = 8.2275
P/B = 15.8479
P/EG = -1.32
Revenue TTM = 1.09b USD
EBIT TTM = 345.1m USD
EBITDA TTM = 370.2m USD
Long Term Debt = 163.1m USD (from longTermDebt, last quarter)
Short Term Debt = 47.5m USD (from shortTermDebt, last quarter)
Debt = 312.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 111.1m USD (from netDebt column, last quarter)
Enterprise Value = 8.37b USD (8.98b + Debt 312.8m - CCE 916.6m)
Interest Coverage Ratio = 3.83 (Ebit TTM 345.1m / Interest Expense TTM 90.2m)
EV/FCF = 26.00x (Enterprise Value 8.37b / FCF TTM 322.0m)
FCF Yield = 3.85% (FCF TTM 322.0m / Enterprise Value 8.37b)
FCF Margin = 29.52% (FCF TTM 322.0m / Revenue TTM 1.09b)
Net Margin = 18.54% (Net Income TTM 202.3m / Revenue TTM 1.09b)
Gross Margin = unknown ((Revenue TTM 1.09b - Cost of Revenue TTM 25.1m) / Revenue TTM)
Tobins Q-Ratio = 5.22 (Enterprise Value 8.37b / Total Assets 1.60b)
Interest Expense / Debt = 7.20% (Interest Expense 22.5m / Debt 312.8m)
Taxrate = 0.10% (29.0k / 28.3m)
NOPAT = 344.8m (EBIT 345.1m * (1 - 0.10%))
Current Ratio = 3.38 (Total Current Assets 1.17b / Total Current Liabilities 347.4m)
Debt / Equity = 0.55 (Debt 312.8m / totalStockholderEquity, last quarter 568.4m)
Debt / EBITDA = 0.30 (Net Debt 111.1m / EBITDA 370.2m)
Debt / FCF = 0.35 (Net Debt 111.1m / FCF TTM 322.0m)
Total Stockholder Equity = 560.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.45% (Net Income 202.3m / Total Assets 1.60b)
RoE = 36.12% (Net Income TTM 202.3m / Total Stockholder Equity 560.0m)
RoCE = 47.73% (EBIT 345.1m / Capital Employed (Equity 560.0m + L.T.Debt 163.1m))
RoIC = 42.93% (NOPAT 344.8m / Invested Capital 803.1m)
WACC = 13.44% (E(8.98b)/V(9.29b) * Re(13.66%) + D(312.8m)/V(9.29b) * Rd(7.20%) * (1-Tc(0.00)))
Discount Rate = 13.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.45%
[DCF] Terminal Value 65.60% ; FCFF base≈322.0m ; Y1≈397.2m ; Y5≈676.5m
[DCF] Fair Price = 37.47 (EV 5.36b - Net Debt 111.1m = Equity 5.25b / Shares 140.0m; r=13.44% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 6.01 | EPS CAGR: -15.30% | SUE: 0.08 | # QB: 0
Revenue Correlation: 4.81 | Revenue CAGR: 15.90% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.37 | Chg7d=-0.081 | Chg30d=-0.075 | Revisions Net=-1 | Analysts=10
EPS current Year (2026-09-30): EPS=-3.24 | Chg7d=+0.070 | Chg30d=+0.198 | Revisions Net=+2 | Growth EPS=-32290.9% | Growth Revenue=-46.0%
EPS next Year (2027-09-30): EPS=-4.30 | Chg7d=+0.093 | Chg30d=+0.214 | Revisions Net=-2 | Growth EPS=-32.7% | Growth Revenue=-29.3%
[Analyst] Revisions Ratio: -0.14 (3 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 11.2% (Discount Rate 13.7% - Earnings Yield 2.5%)
[Growth] Growth Spread = +3.3% (Analyst 14.5% - Implied 11.2%)
P/E Forward = 111.1111
P/S = 8.2275
P/B = 15.8479
P/EG = -1.32
Revenue TTM = 1.09b USD
EBIT TTM = 345.1m USD
EBITDA TTM = 370.2m USD
Long Term Debt = 163.1m USD (from longTermDebt, last quarter)
Short Term Debt = 47.5m USD (from shortTermDebt, last quarter)
Debt = 312.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 111.1m USD (from netDebt column, last quarter)
Enterprise Value = 8.37b USD (8.98b + Debt 312.8m - CCE 916.6m)
Interest Coverage Ratio = 3.83 (Ebit TTM 345.1m / Interest Expense TTM 90.2m)
EV/FCF = 26.00x (Enterprise Value 8.37b / FCF TTM 322.0m)
FCF Yield = 3.85% (FCF TTM 322.0m / Enterprise Value 8.37b)
FCF Margin = 29.52% (FCF TTM 322.0m / Revenue TTM 1.09b)
Net Margin = 18.54% (Net Income TTM 202.3m / Revenue TTM 1.09b)
Gross Margin = unknown ((Revenue TTM 1.09b - Cost of Revenue TTM 25.1m) / Revenue TTM)
Tobins Q-Ratio = 5.22 (Enterprise Value 8.37b / Total Assets 1.60b)
Interest Expense / Debt = 7.20% (Interest Expense 22.5m / Debt 312.8m)
Taxrate = 0.10% (29.0k / 28.3m)
NOPAT = 344.8m (EBIT 345.1m * (1 - 0.10%))
Current Ratio = 3.38 (Total Current Assets 1.17b / Total Current Liabilities 347.4m)
Debt / Equity = 0.55 (Debt 312.8m / totalStockholderEquity, last quarter 568.4m)
Debt / EBITDA = 0.30 (Net Debt 111.1m / EBITDA 370.2m)
Debt / FCF = 0.35 (Net Debt 111.1m / FCF TTM 322.0m)
Total Stockholder Equity = 560.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.45% (Net Income 202.3m / Total Assets 1.60b)
RoE = 36.12% (Net Income TTM 202.3m / Total Stockholder Equity 560.0m)
RoCE = 47.73% (EBIT 345.1m / Capital Employed (Equity 560.0m + L.T.Debt 163.1m))
RoIC = 42.93% (NOPAT 344.8m / Invested Capital 803.1m)
WACC = 13.44% (E(8.98b)/V(9.29b) * Re(13.66%) + D(312.8m)/V(9.29b) * Rd(7.20%) * (1-Tc(0.00)))
Discount Rate = 13.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.45%
[DCF] Terminal Value 65.60% ; FCFF base≈322.0m ; Y1≈397.2m ; Y5≈676.5m
[DCF] Fair Price = 37.47 (EV 5.36b - Net Debt 111.1m = Equity 5.25b / Shares 140.0m; r=13.44% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 6.01 | EPS CAGR: -15.30% | SUE: 0.08 | # QB: 0
Revenue Correlation: 4.81 | Revenue CAGR: 15.90% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.37 | Chg7d=-0.081 | Chg30d=-0.075 | Revisions Net=-1 | Analysts=10
EPS current Year (2026-09-30): EPS=-3.24 | Chg7d=+0.070 | Chg30d=+0.198 | Revisions Net=+2 | Growth EPS=-32290.9% | Growth Revenue=-46.0%
EPS next Year (2027-09-30): EPS=-4.30 | Chg7d=+0.093 | Chg30d=+0.214 | Revisions Net=-2 | Growth EPS=-32.7% | Growth Revenue=-29.3%
[Analyst] Revisions Ratio: -0.14 (3 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 11.2% (Discount Rate 13.7% - Earnings Yield 2.5%)
[Growth] Growth Spread = +3.3% (Analyst 14.5% - Implied 11.2%)